Muscarinic Acetylcholine Receptor Knockout Mice

J. Wess,W. Zhang,A. Duttaroy,T. Miyakawa,J. Gomeza,Y. Cui,A. S. Basile,F. P. Bymaster,D. L. McKinzie,C. C. Felder,C. Deng,M. Yamada
DOI: https://doi.org/10.1007/978-3-642-18934-0_3
2004-01-01
Abstract: Muscarinic acetylcholine receptors (mAChRs) play critical roles in regulating the activity of many important functions of the central and peripheral nervous system. However, identification of the physiological and pathophysiological roles of the individual mAChR subtypes (M1-M5) has proven a difficult task, primarily due to the lack of ligands endowed with a high degree of receptor subtype selectivity and the fact that most tissues and organs express multiple mAChRs. To circumvent these difficulties, we and others have used gene targeting strategies to generate mutant mouse lines containing inactivating mutations of the M1-M5 mAChR genes. The different mAChR mutant mice and the corresponding wild-type control animals were subjected to a battery of physiological, pharmacological, behavioral, biochemical, and neurochemical tests. The M1-M5 mAChR mutant mice (MXR-/- mice) were all viable and reproduced normally. However, each mutant mouse line displayed distinct phenotypical changes. For example, M1R-/- mice showed a pronounced increase in locomotor activity, probably due to the increase in dopamine release in the striatum. In addition, pilocarpine-induced epileptic seizures were absent in M1R-/- mice. Pharmacological analysis of M2R-/- mice indicated that the M2 subtype plays a key role in mediating three of the most striking central muscarinic effects: tremor, hypothermia, and analgesia. As expected, muscarinic agonist-mediated bradycardia was abolished in M2R-/- mice. M3R-/- mice displayed a significant decrease in food intake, reduced body weight and peripheral fat deposits, and very low serum leptin and insulin levels. Additional studies showed that the M3 receptor subtype also plays a key role in mediating smooth muscle contraction and glandular secretion. Behavioral analysis of M4R-/- mice suggested that M4 receptors mediate inhibition of D1 dopamine receptor-mediated locomotor stimulation, probably at the level of striatal projection neurons. Studies with M5R-/- mice indicated that vascular M5 receptors mediate cholinergic relaxation of cerebral arteries and arterioles. Behavioral and neurochemical studies showed that M5 receptor activity modulates both morphine reward and withdrawal processes, probably through activation of M5 receptors located on midbrain dopaminergic neurons. These results offer promising new perspectives for the rational development of novel muscarinic drugs.
What problem does this paper attempt to address?